Product image of Mycophenolatmofetil Hexal (Mycophenolate Mofetil) supplied by GNH India

Mycophenolatmofetil Hexal

Active Ingredient:
Mycophenolate Mofetil
Origin:
EU

Mycophenolatmofetil Hexal (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycophenolatmofetil Hexal, is an antimetabolite immunosuppressant presented as an oral formulation for systemic use. It is used to prevent organ transplant rejection and to treat certain autoimmune diseases such as lupus nephritis.

GNH India supplies Mycophenolatmofetil Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Manufacturer / TM Owner

Hexal Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mycophenolate Mofetil is employed in immunosuppressive regimens targeting organ transplantation and autoimmune disorders.

  • Organ transplant rejection prevention: reduces the risk of acute and chronic graft rejection.
  • Lupus nephritis: improves renal outcomes in patients with systemic lupus erythematosus.
  • Other autoimmune conditions (off‑label): may be used in selected cases of vasculitis or dermatomyositis under specialist supervision.

How It Works

  • Mycophenolate Mofetil selectively inhibits inosine monophosphate dehydrogenase, an enzyme essential for de novo guanosine nucleotide synthesis. By limiting guanosine pools, the drug suppresses proliferation of T‑ and B‑lymphocytes, which rely heavily on this pathway, thereby dampening cellular and humoral immune responses involved in graft rejection and autoimmune inflammation.

Side Effects

Adverse reactions can vary in frequency and severity.

Common Side Effects

  • Gastrointestinal upset: nausea, vomiting, diarrhoea, or abdominal pain.
  • Haematologic changes: leukopenia, anaemia, or thrombocytopenia.
  • Infections: increased susceptibility to bacterial, viral or fungal infections.
  • Headache or dizziness.
  • Elevated liver enzymes.

Serious or Rare Side Effects

  • Severe infections such as opportunistic or reactivating viruses.
  • Progressive multifocal leukoencephalopathy (PML).
  • Life‑threatening bone marrow suppression.
  • Malignancies, particularly post‑transplant lymphoproliferative disorder.
  • Severe hypersensitivity reactions including Stevens‑Johnson syndrome.
  • Pregnancy‑related teratogenicity (Category X).

Precautions & Warnings

Patients and prescribers should consider several safety measures before and during therapy.

  • Pregnancy: contraindicated in pregnancy (Category X); effective contraception is required.
  • Breastfeeding: not recommended as the drug is excreted in milk.
  • Renal impairment: dose adjustment may be needed; monitor renal function regularly.
  • Hepatic dysfunction: assess liver enzymes before initiation and periodically thereafter.
  • Infection risk: screen for latent infections (e.g., TB, hepatitis B) and vaccinate appropriately before starting.
  • Store at ambient temperature: keep below 25 °C, retain in the original container, and protect from moisture and direct sunlight.

Avoid Interactions

Mycophenolate Mofetil can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Antacids containing magnesium or aluminum: reduce drug absorption; separate dosing by at least 2 hours.
  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly decrease exposure and may lead to graft rejection.
  • Live vaccines: increased risk of severe infection; avoid concurrent use.

Moderate Interactions (Monitor Closely)

  • Azathioprine or other myelosuppressants: additive bone‑marrow suppression; monitor blood counts.
  • ACE inhibitors or ARBs: may exacerbate renal dysfunction; assess renal function.
  • High‑dose steroids: may increase infection risk; observe clinical signs closely.

Frequently Asked Questions

Mycophenolatmofetil Hexal contains mycophenolate mofetil, which is prescribed to prevent rejection after organ transplantation and to treat autoimmune kidney disease such as lupus nephritis. It may also be considered in other severe autoimmune disorders under specialist guidance.

Mycophenolate mofetil inhibits the enzyme inosine monophosphate dehydrogenase, blocking the synthesis of guanosine nucleotides. This limits the proliferation of T‑ and B‑lymphocytes, reducing the immune response that can cause graft rejection or autoimmune tissue damage.

The specific dose of Mycophenolatmofetil Hexal is determined by the prescribing physician based on the patient’s clinical condition, transplant type, renal function and other individual factors. Dosage regimens are not standardized and should follow the prescriber’s instructions.

Mycophenolate mofetil is classified as pregnancy category X because it can cause fetal malformations and embryonic loss. It is contraindicated in pregnancy, and women of child‑bearing potential must use effective contraception. The drug is also not recommended while breastfeeding as it is excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with calcineurin inhibitors such as tacrolimus, mycophenolate mofetil offers a different mechanism—targeting nucleotide synthesis rather than calcineurin signaling. It is often used in combination with other agents to achieve synergistic immunosuppression while allowing lower doses of each drug, potentially reducing certain toxicities.

Mycophenolatmofetil Hexal should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture, heat and direct sunlight, and ensure the container is tightly closed to maintain stability.

The medication is taken orally, usually with food or a glass of water to minimise gastrointestinal discomfort. The exact dosing schedule—such as once or twice daily—must be prescribed by a qualified healthcare professional and adhered to strictly.

Serious risks include severe infections, opportunistic pathogens, life‑threatening bone‑marrow suppression, and rare but fatal conditions like progressive multifocal leukoencephalopathy. Patients should be monitored closely for signs of infection, abnormal blood counts and any neurological changes.

The drug is contraindicated in pregnant women, individuals with known hypersensitivity to mycophenolate mofetil or its excipients, and patients with uncontrolled severe infections. Caution is also advised for those with significant renal or hepatic impairment, and it should be avoided in patients unable to use effective contraception.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolate Mofetil

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT